Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028673 | 0.85 | MAPK14 (0.52) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028318 | 0.83 | SRC (0.55) | MAPK14SRCBRAFKDRCSNK1D | |
| SCHEMBL4333423 | 0.81 | MAPK14 (0.61) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6178119 | 0.79 | MAPK14 (0.52) | MAPK14SRCBRAFKDR | |
| SCHEMBL6028037 | 0.79 | MAPK14 (0.58) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL14411918 | 0.77 | MAPK14 (0.57) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6029688 | 0.76 | MAPK14 (0.52) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028669 | 0.76 | MAPK14 (0.54) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL4343316 | 0.75 | MAPK14 (0.59) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL6028378 | 0.73 | MAPK14 (0.51) | MAPK14SRCBRAFKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087624-B2 | Substituted pyrazole compounds | TEIKOJU HORMONE MFG. CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1188754-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040087628-A1 | Substituted pyrazole compounds | MINAMI NOBUYOSHI (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6667325-B1 | P38MAP kinase inhibiters; tumor necrosis factor alpha, interleukin 1 and 6 and cyclooxygenase II related diseases | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| EP-1188754-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087628-A1 | Substituted pyrazole compounds | CNKSR1, MAPK1, IRAK1 | MAPK14 64/4885SRC 684/4885BRAF 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.